{"id":"W2590667525","doi":"10.1200/jco.2015.33.3_suppl.358","title":"Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Gastroenterology; Clinical endpoint; Veliparib; Hazard ratio; Surgery; Oncology; Confidence interval; Clinical trial; Adverse effect; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001047256,0.001228206,0.001335175,0.0003528992,0.000348527,0.00105578,0.0007622507,0.001134153,0.004993335],"category_scores_gemma":[0.0008340032,0.0006233842,0.0008665931,0.0003667946,0.0007731638,0.0007253592,0.000402293,0.002733347,0.001218154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006784784,"about_ca_system_score_gemma":0.001465316,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008197547,"about_ca_topic_score_gemma":0.001947185,"domain_scores_codex":[0.9996992,0.0001559678,0.00001076323,0.00004458986,0.00002204903,0.0000675091],"domain_scores_gemma":[0.9995129,0.00007749045,0.00008870068,0.000033279,0.00002366187,0.0002639646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.89239,0.02764353,0.002888337,0.000548135,0.0005023799,0.0001876265,0.000169837,0.002218761,0.01371876,0.0003239219,0.00346627,0.05594241],"study_design_scores_gemma":[0.7519962,0.2379502,0.004088154,0.0000436168,0.0001719398,0.0001859835,0.0000428077,0.001145589,0.001607601,0.0003193078,0.002433379,0.00001525004],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839053,0.0027527,0.001010967,0.0006807006,0.0002113931,0.005939487,0.001896024,0.0002198258,0.003383606],"genre_scores_gemma":[0.9826601,0.001877434,0.001829263,0.001013139,0.0001922916,0.005386859,0.002249924,0.00004045331,0.004750378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004993335,"threshold_uncertainty_score":0.01670444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08617428512118895,"score_gpt":0.4132959597519584,"score_spread":0.3271216746307695,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}